Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

News

A plant sciences spin-out flourishes at the BioEscalator

‘Mighty oaks from little acorns grow.’ And so it is with novel herbicide developer Moa Technology, which has grown from four people when it first became a BioEscalator tenant to a company of 85 with research facilities in Oxford and Yorkshire.

Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens®

Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. The round was co-led by new investors, Pfizer Ventures and M Ventures, with participation from all existing investors, including RA Capital, Samsara BioCapital and SV Health Investors. The Francis Crick Institute is also joining the round as a new investor. Enara Bio will use the proceeds to advance its pipeline of TCR-based immunotherapies against novel and differentiated Dark Antigen targets for solid tumours.

Infinitopes selected by Labiotech as one of Europe’s rising biotech stars: 10 startups to watch in 2024

Moa and Biomar announce bio-herbicide collaboration

Moa has boosted its bio-herbicide research and development programme with a new long-term collaboration agreement with Biomar Microbial Technologies.

CardiaTec secures $6.5M seed funding to advance its multi-omics drug discovery platform for cardiovascular diseases

CardiaTec, a TechBio company employing computational methods to decode the biology behind cardiovascular disease, has raised $6.5M in seed funding led by San Francisco-based Montage Ventures.

EteRNA Biologics logo

Eterna Biologics: Revolutionising RNA therapeutics

We are excited to welcome Eterna Biologics, a University of Oxford biotech spinout company with a mission to unleash the full potential of RNA medicines. The company aims to enhance global health by expanding the applicability of RNA-targeting medicine to develop treatment for a wide range of human conditions.

A photo of the Evolvere Biosciences team leaning on the Y Combinator signpost.

Evolvere Biosciences accepted into the prestigious Y Combinator program

The team of University of Oxford students is making strides that could transform our approach to antibiotics.

U-Ploid thrilled to join the BioEscalator Community

U-Ploid Biotechnologies joins the BioEscalator to develop groundbreaking therapeutics that improve egg quality and revolutionise IVF.

A photo showing the difference in weed growth using Moa's novel herbicide. Left: control area with heavy weed infestation (Springfield, Tennessee) Right: area treated with Moa novel herbicide, which has prevented weeds from emerging (Same site, Springfield, Tennessee)

Moa announces international field trial success at the ACS autumn conference in Denver

Oxford University spin-out Moa Technology has announced excellent results in multi-country field trials of promising new classes of herbicide with novel modes of action recently discovered by the company.

CyanoCapture continues to make strides in the green sciences industry

CyanoCapture was selected as one of the two winners of the Green Sciences Incubator challenge, which L'Oréal organised in collaboration with Genopole and Hello Tomorrow.

Photo of Ash Maroof, Founder and CSO.

RE-AIM Therapeutics: Targeting disease causal cells to cure autoimmunity

We are delighted to welcome RE-AIM Therapeutics to the BioEscalator community, a start-up focused on developing antibody-based curative therapies for inflammatory disorders, such as psoriasis and inflammatory bowel disease.

The BioEscalator welcomes SiGenex to its growing community

SiGenex is advancing genomic medicine with its innovative, artificial intelligence-powered in-hospital sequencing platform. The company's technology is designed to transform how hospitals, clinics, and medical centres perform targeted next-generation sequencing (NGS) tests.

A photo of the Bioarchitech team on their last day in the BioEscalator. Left to right: Ines Loureiro, Kevin Maskell, Andri Vasou, and William Jackson.

Bioarchitech graduates from the BioEscalator: A new chapter for innovative cancer therapy

Bioarchitech's departure from the BioEscalator marks the beginning of an exciting new phase for the pioneering cancer therapy company, as it transitions to the next stage of its innovative journey.

Highlights from the 5th annual BioEscalator Pitch Battle 2024

The 5th Annual BioEscalator Pitch Battle was an exciting showcase of fierce competition and groundbreaking innovations. With seven categories, ten companies competing for the top spot, and £2000 in prize money at stake, the judges faced a formidable task in selecting the winners.

Nucleome Therapeutics appoints Mark Bodmer as Chief Executive Officer

Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company using spatial genomics to discover precision medicines for complex diseases, announces today that it has appointed Dr. Mark Bodmer as Chief Executive Officer with effect from 24 July.

Photo of Moa Technology CEO Dr Virginia Corless.

Moa harvests global deal for new herbicide

Agricultural biotech firm Moa Technology has signed a research and commercial partnership with Nufarm, a global agricultural innovator based in Melbourne, Australia.

Photo: Left to right - Michael Dustin, Professor of Molecular Immunology; Ashwin Jainarayanan, Founder & CSO of Granza Bio; and Ashwin Nandakumar, Founder & CEO of Granza Bio.

Granza Bio grabs $7M seed from Felicis and YC to advance delivery of cancer treatments

In April 2024, the BioEscalator welcomed Granza Bio, a biotech startup focusing on developing novel immunotherapy delivery methods. The company has already attracted investor interest and closed a successful $7.14 million seed funding round led by Felicis and Refactor, with participation from Y Combinator.

A photo of Dr Claire Shingler with a quote that reads: "Working with spin-outs and start-ups is hugely inspiring and rewarding. It is fast-paced, outward-looking, and very collaborative."

Collaboration in action: Academic-industry stories

Our Business Manager, Dr Claire Shingler, participated in a collaborative project highlighting the strong partnerships between academic and industry professionals in the Medical Sciences Division. In this project, Claire shared her story and discussed her role in managing Oxford's biomedical science incubator. She discussed her motivations and the rewarding experiences she has had in supporting innovative spin-outs.

OSPT Ltd brings together ideas and experience for ‘astonishing’ success at the BioEscalator

The idea behind antibacterial company OSPT came to CEO and Founder Stephanie Lesage as she talked to haemodialysis patients as part of a research project, when it became clear to her that they had a really deep fear of the development of infection via their catheters. Their concerns were so significant that they almost outweighed the benefits of the dialysis treatment in the patients’ minds.

GSK enters into a multi-year data licence agreement with Ochre Bio to further investigate the drivers of liver disease

Ochre and GSK will create a foundational liver biology dataset that could have the potential to further improve translation of novel therapies for liver diseases.

Load More